Johnson & Johnson said on Thursday it had filed for European approval for its experimental vaccine regimen to protect against a strain of Ebola virus that most commonly causes outbreaks of the deadly disease.
Johnson & Johnson said on Thursday it had filed for European approval for its experimental vaccine regimen to protect against a strain of Ebola virus that most commonly causes outbreaks of the deadly disease.
Pharmamarketeer richt zich op marketingprofessionals van farmaceuten en andere medisch-gerelateerde organisaties in Nederland en België.
Copyright 2023 © Uitgave van MedHealth Communications BV | Privacy disclaimer
![Design thinking als contentmarketeer inzetten [voorbeelden & tips]](https://www.pharmamarketeer.nl/wp-content/uploads/2024/11/business-team-working-in-a-start-up-office-2023-11-27-05-22-22-utc-1-80x60.jpg)
